logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Osteoporosis Postmenopausal

    FiltersReset Filters
    39 results

    • alendronate

      (ALENDRONATE SODIUM)
      Hangzhou Minsheng Binjiang Pharmaceutical Co., Ltd.
      Usage: Alendronate sodium tablets are indicated for treating and preventing osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, treating glucocorticoid-induced osteoporosis, and treating Paget’s disease of bone. Use should be periodically re-evaluated, particularly for low-risk fracture patients after 3 to 5 years.

    • alendronate

      (Alendronate sodium tablet)
      Marlex Pharmaceuticals Inc
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women, increasing bone mass in men with osteoporosis, preventing postmenopausal osteoporosis, treating glucocorticoid-induced osteoporosis, and managing Paget's disease of bone in symptomatic patients or those at risk for complications. Reinforcement of therapy need is recommended periodically.

    • alendronate sodium

      (Alendronate Sodium)
      Hikma Pharmaceuticals USA Inc.
      Usage: Alendronate sodium is indicated for treating osteoporosis in postmenopausal women and increasing bone mass in men with osteoporosis. It helps increase bone mass and reduce fracture incidence, particularly in the hip and spine. Re-evaluations for continued therapy are recommended every few years.

    • atelvia

      (risedronate sodium)
      Allergan, Inc.
      Usage: Atelvia is indicated for treating osteoporosis in postmenopausal women, reducing vertebral and nonvertebral osteoporosis-related fractures. The optimal duration of use is undetermined, with recommendations for periodic re-evaluation of therapy need, especially for patients at low fracture risk after 3 to 5 years.

    • calcitonin salmon

      (Calcitonin Salmon)
      ENDO USA, Inc.
      Usage: Calcitonin salmon injection is indicated for treating symptomatic Paget's disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in patients who cannot use alternative therapies. Its efficacy in fracture reduction for osteoporosis is not established, and ongoing therapy should be periodically re-evaluated due to potential malignancy risks.

    • calcitonin salmon

      (CALCITONIN SALMON)
      Cipla USA Inc.
      Usage: Calcitonin salmon injection is indicated for treating symptomatic Paget’s disease of bone, hypercalcemic emergencies, and postmenopausal osteoporosis in women more than five years postmenopause. It is intended for patients who do not respond to, or cannot use, alternative treatments. Regular re-evaluation is recommended due to potential malignancy risks.

    • climara

      (Estradiol)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: This drug is indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, hypoestrogenism from hypogonadism or primary ovarian failure, and for the prevention of postmenopausal osteoporosis, with specific limitations on its use for atrophy and osteoporosis.

    • climara pro

      (Estradiol and Levonorgestrel)
      Bayer HealthCare Pharmaceuticals Inc.
      Usage: Climara Pro is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis, specifically in women at significant risk. Non-estrogen medications should be considered first for osteoporosis prevention.

    • duavee

      (conjugated estrogens/bazedoxifene)
      Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
      Usage: DUAVEE is indicated for women with a uterus to treat moderate to severe menopausal vasomotor symptoms and to prevent postmenopausal osteoporosis. Treatment duration should be minimal and reconsidered periodically, focusing on women at significant risk of osteoporosis.

    • estradiol and norethindrone acetate

      (Estradiol and Norethindrone Acetate)
      Ingenus Pharmaceuticals, LLC
      Usage: Estradiol and norethindrone acetate tablets are indicated for the treatment of moderate to severe vasomotor symptoms and vulvar/vaginal atrophy due to menopause, as well as for the prevention of postmenopausal osteoporosis in women at significant risk. Topical alternatives should be considered for certain conditions.